1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas

Oncogene

Volumn 27, Issue 14, 2008, Pages 2097-2108

  Ichimura, K ^a   Vogazianou, A P ^a   Liu, L ^a   Pearson, D M ^a   Backlund L M ^b   Plant, K ^a   Baird, K ^a   Langford, C F ^c   Gregory, S G ^c,d   Collins, V P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Array CGH; Astrocytoma; Methylation; Microarray; Oligodendroglioma

Indexed keywords

CYTOKINE RECEPTOR; PROTEIN KINASE B; PROTEIN TNFRSF9; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CANCER CELL CULTURE; CANCER SURVIVAL; CHROMOSOME 1; CHROMOSOME 1P; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CPG ISLAND; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METHYLATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOMATIC MUTATION; UPREGULATION;

ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GLIOBLASTOMA; HOMOZYGOTE; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 41149167213     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210848     Document Type: Article

References (47)

1. Alonso ME, Bello MJ, Lomas J, Gonzalez-Gomez P, Arjona D, De Campos JM et al. (2001). Absence of mutation of the p73 gene in astrocytic neoplasms. Int J Oncol 19: 609-612.
2. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D et al. (2007). CHD5 is a tumor suppressor at human 1p36. Cell 128: 459-475.
3. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. (2005). Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11: 1119-1128.
4. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. (2005). Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86.
5. Bigner SH, Mark J, Burger PC, Mahaley Jr MS, Bullard DE, Muhlbaier LH et al. (1988). Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 48: 405-411.
6. Buckley PG, Jarbo C, Menzel U, Mathiesen T, Scott C, Gregory SG et al. (2005). Comprehensive DNA copy number profiling of meningioma using a chromosome 1 tiling path microarray identifies novel candidate tumor suppressor loci. Cancer Res 65: 2653-2661.
7. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al. (2006). Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707-2714.
8. Dong Z, Pang JS, Ng MH, Poon WS, Zhou L, Ng HK. (2004). Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours. Br J Cancer 91: 1105-1111.
9. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B et al. (2004). Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14: 121-130.
10. Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE et al. (2003). DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer 36: 361-374.
11. Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A et al. (2006). The DNA sequence and biological annotation of human chromosome 1. Nature 441: 315-321.
12. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD et al. (2006). Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65: 988-994.
13. Harden SV, Guo Z, Epstein JI, Sidransky D.. (2003). Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 169: 1138-1142.
14. Hashimoto K, Mori N, Tamesa T, Okada T, Kawauchi S, Oga A et al. (2004). Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol 17: 617-622.
15. Hashimoto N, Murakami M, Takahashi Y, Fujimoto M, Inazawa J, Mineura K.. (2003). Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97: 2254-2261.
16. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S et al. (2001). Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60: 863-871.
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826.
18. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S et al. (2006). Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 65: 846-854.
19. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP. (2000). Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60: 417-424.
20. Ichimura K, Mungall AJ, Fiegler H, Pearson DM, Dunham I, Carter NP et al. (2006). Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH. Oncogene 25: 1261-1271.
21. Ichimura K, Ohgaki H, Kleihues P, Collins VP. (2004). Molecular pathogenesis of astrocytic tumours. J Neurooncol 70: 137-160.
22. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP. (1998). Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 22: 9-15.
23. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M et al. (2005). Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58: 483-487.
24. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S et al. (2000). Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 92: 983-990.
25. Iuchi T, Namba H, Iwadate Y, Shishikura T, Kageyama H, Nakamura Y et al. (2002). Identification of the small interstitial deletion at chromosome band 1p34-p35 and its association with poor outcome in oligodendroglial tumors. Genes Chromosomes Cancer 35: 170-175.
26. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M et al. (2006). A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66: 9852-9861.
27. Kleihues P, Cavenee WK. (2000). Pathology and Genetics of Tumours of the Nervous System. IARC Press: Lyon.
28. Knobbe CB, Reifenberger G. (2003). Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/ protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 13: 507-518.
29. Koschny R, Koschny T, Froster UG, Krupp W, Zuber MA. (2002). Comparative genomic hybridization in glioma: a meta-analysis of 509 cases. Cancer Genet Cytogenet 135: 147-159.
30. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D et al. (2007). Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66: 545-551.
31. Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike HM et al. (2005). Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83: 917-926.
32. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE et al. (1997). Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3: 682-685.
33. MRC (The Medical Research Council Brain Tumour Working Party) (2001). Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19: 509-518.
34. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al. (2002). Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161: 313-319.
35. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB et al. (2001). Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158: 1253-1262.
36. Reifenberger G, Louis DN.. (2003). Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62: 111-126.
37. Schmidt EE, Ichimura K, Goike HM, Moshref A, Liu L, Collins VP. (1999). Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 58: 1170-1183.
38. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B et al. (2002). Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61: 321-328.
39. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G et al. (1999). Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18: 4144-4152.
40. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM et al. (2000). Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18: 636-645.
41. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N et al. (2002). Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8: 196-201.
42. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al. (2006). Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715-2722.
43. von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J et al. (2000). Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59: 544-558.
44. Waerner T, Gardellin P, Pfizenmaier K, Weith A, Kraut N. (2001). Human RERE is localized to nuclear promyelocytic leukemia oncogenic domains and enhances apoptosis. Cell Growth Differ 12: 201-210.
45. Watanabe T, Huang H, Nakamura M, Wischhusen J, Weller M, Kleihues P et al. (2002). Methylation of the p73 gene in gliomas. Acta Neuropathol (Berl) 104: 357-362.
46. Watts TH. (2005). TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23-68.
47. Yanagisawa H, Bundo M, Miyashita T, Okamura-Oho Y, Tadokoro K, Tokunaga K et al. (2000). Protein binding of a DRPLA family through arginine-glutamic acid dipeptide repeats is enhanced by extended polyglutamine. Hum Mol Genet 9: 1433-1442.